Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...